Nutriband Inc. NTRB Archives

WednesdaySep 10, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation

Recent warrant exercises at $6.43 generated $5.3 million, signaling investor conviction in AVERSA(TM) Fentanyl ahead of NDA filing AVERSA(TM) is a abuse-deterrent solution for transdermal patches, addressing a longstanding gap in pain management safety Strategic funding positions Nutriband to complete development and FDA submission, targeting $80–200 million in peak U.S. annual sales The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially…

MondaySep 08, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference

Nutriband sustains itself through multiple revenue-generating subsidiaries At the core of the company’s innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents…

ThursdaySep 04, 2025 9:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA

Nutriband (NASDAQ: NTRB), a company developing abuse deterrent pharmaceutical products, announced the exercise of warrants at a strike price of $6.43, generating $5,306,000 in proceeds. The funds will support the remaining clinical development of AVERSA Fentanyl and submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration. AVERSA Fentanyl, which could become the world’s first opioid patch with abuse deterrent properties, is estimated to reach peak annual U.S. sales of $80 million to $200 million, according to a 2022 Health Advances market analysis report. To view the full press release, visit https://ibn.fm/svjE3 About Nutriband Inc. We…

WednesdayAug 20, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity

FDA grants Type C Meeting for AVERSA(TM) Fentanyl to discuss Chemistry, Manufacturing, and Controls pathway from IND submission through NDA approval and commercialization CEO Gareth Sheridan temporarily steps aside to pursue Irish Presidential nomination while Chairman Serguei Melnik assumes interim CEO role during critical development phase Strategic partnership with Kindeva combines proven FDA-approved fentanyl patch technology with Nutriband's proprietary abuse-deterrent platform targeting $80-200 million peak U.S. market opportunity The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic…

MondayAug 18, 2025 10:55 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20

Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit https://ibn.fm/CiVho About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse…

MondayAug 11, 2025 9:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Steps Aside Temporarily to Run for Irish Presidency

Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will step aside for three months to pursue candidacy in the Irish Presidential election, with nomination hearings and voting taking place in September and October. Co-Founder and Chairman Serguei Melnik, a corporate strategy expert with over 20 years in capital markets, will assume CEO duties during this period, guiding the company toward its 2026 NDA filing target. Sheridan emphasized confidence in the leadership team, noting continued progress on AVERSA Fentanyl, which the FDA recently granted a meeting request for. AVERSA Fentanyl is positioned to be the first abuse-deterrent opioid patch, designed to…

FridayAug 08, 2025 9:30 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch to help prevent abuse, diversion, misuse, and accidental exposure while maintaining access for patients in need. Positioned to be the world’s first abuse-deterrent opioid patch, AVERSA Fentanyl targets peak annual U.S. sales potential of $80 million to $200 million, with future global market expansion…

WednesdayAug 06, 2025 9:50 am

Nutriband Inc. (NASDAQ: NTRB) Navigates Drug-Delivery Challenges with Innovation in Abuse-Deterrent Tech

Drug delivery plays a critical role in modern healthcare, but when it comes to potent opioids such as fentanyl, the stakes are particularly high Nutriband is developing Aversa(TM), a proprietary abuse-deterrent transdermal technology designed to prevent diversion, misuse, abuse and accidental exposure Nutriband’s Aversa(TM) fentanyl patch is estimated to have a market potential of $80 million to $200 million annually within five years of launch Developing safe, effective and abuse-deterrent delivery systems for controlled substances such as fentanyl is a formidable challenge, and Nutriband (NASDAQ: NTRB) is positioning itself at the forefront of that effort. The company is pioneering transdermal…

TuesdayAug 05, 2025 9:00 am

Nutriband Inc. (NASDAQ: NTRB) Aligns Shareholder Value with FDA Milestone

FDA approval is a powerful inflection point in the lifecycle of any biopharmaceutical company Nutriband’s recent 25% preferred stock dividend uniquely ties shareholder reward to regulatory achievement CEO notes that “core goal is to continue to create value for our shareholders particularly as we near closer to the commercialization of AVERSA(TM) Fentanyl” Obtaining approval from the U.S. Food and Drug Administration (“FDA”) is a monumental achievement for any biopharmaceutical company, serving as a critical validation of a drug's safety and efficacy. This rigorous process is a cornerstone of public health, ensuring that only treatments proven to be beneficial and with acceptable…

FridayJul 18, 2025 10:20 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Sets Key Dates for 25% Preferred Stock Dividend

Nutriband (NASDAQ: NTRB) is reminding shareholders of its upcoming 25% preferred stock dividend. Shareholders of record as of July 25, 2025, will receive one preferred share for every four common shares held, with the dividend payable on August 5. Each preferred share will be convertible to one common share upon FDA approval of Nutriband’s AVERSA Fentanyl product. Unconverted preferred shares will be eligible for annual cash dividends from company profits at the discretion of the board. To view the full report, visit https://ibn.fm/LsLzM About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products.…

Site Search

Company Search

Tag: Nutriband Inc. NTRB